Answers are grounded in this paper and cite their sources.
BMN 673 is currently in early-phase clinical development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: